Special Issue "Medicine Use in Upper Respiratory Airways and Asthma"
A special issue of Pharmacy (ISSN 2226-4787).
Deadline for manuscript submissions: closed (31 May 2020) | Viewed by 14612
Interests: allergic rhinitis; primary health care; asthma
Interests: quality use of respiratory medicines; inhaler technique; primary care; allergic rhinitis and asthma
Chronic, allergic, airway diseases, specifically asthma and rhinitis, are on the rise worldwide, and represent an enormous health and economic burden to individuals, healthcare systems, and society. When it comes to the management of these conditions, which often coexist, the inappropriate use of medications is a major issue and remains a persistent barrier to achieving optimal patient outcomes. This has been highlighted by the recent Lancet Asthma Commission, calling for effective methods of identifying and addressing non-adherence to inhaled preventative asthma medication, and Allergic Rhinitis and its Impact on Asthma (ARIA) in Pharmacy, identifying the need for delivery of strategies and interventions that address suboptimal rhinitis and asthma control arising from suboptimal treatment.
Pharmacists are trusted healthcare professionals who play an increasingly important role in primary care. They are ideally placed to deliver timely interventions that promote and facilitate the quality use of medicines and support patients in self-management, in view of their therapeutic expertise, accessibility, regular contact with patients and contact with patients who do not visit other healthcare providers regularly. Previous research has shown that pharmacists can improve clinical outcomes in asthma and allergic rhinitis patients with interventions targeting inhaler technique and goal setting. New approaches such as integrated care pathways that focus on the quality and coordination of care and change management, as well as the use of technology, are now being explored.
We invite you to share your approaches to promoting and facilitating the quality use of respiratory medicines either in primary or tertiary care settings. We hope this Special Issue will encourage healthcare researchers to share their strategies and healthcare models that will help achieve and sustain optimal patient outcomes for individuals living with these chronic respiratory conditions.
Prof. Sinthia Bosnic-Anticevich
Dr. Vicky Kritikos
Ms. Biljana Cvetkovski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Allergic rhinitis
- Primary care
- Quality use of respiratory medicines
- Inhaler technique
- Short-acting beta agonists